Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay

Hepatology International

Volumn 7, Issue 1, 2013, Pages 98-105

  Seto, Wai Kay ^a   Tanaka, Yasuhito ^b   Wong, Danny Ka Ho ^a   Lai, Ching Lung ^a,c   Shinkai, Noboru ^b   Yuen, John Chi Hang ^a   Tong, Teresa ^a   Fung, James ^a   Hung, Ivan Fan Ngai ^a   Yuen, Man Fung ^a,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

HBcrAg; HBsAg; Linearized HBsAg; Seroclearance; Serology

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; AGE; ANTIGEN DETECTION; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SEROLOGY; SEX RATIO;

EID: 84875241425     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-012-9354-7     Document Type: Article

References (36)

1. BJ McMahon SR Alberts RB Wainwright, et al. 1990 Hepatitis B-related sequelae. Prospective study in 1,400 hepatitis B surface antigen-positive Alaska native carriers Arch Intern Med 150 5 1051 1054 2158773 10.1001/archinte.1990. 00390170087019 1:STN:280:DyaK3c3jtlylug%3D%3D
2. J Liu HI Yang MH Lee, et al. 2010 Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study Gastroenterology 139 2 474 482 20434450 10.1053/j.gastro.2010. 04.048
3. RE Sampliner FA Hamilton OA Iseri, et al. 1979 The liver histology and frequency of clearance of the hepatitis B surface antigen (HBsAg) in chronic carriers Am J Med Sci 277 1 17 22 425995 10.1097/00000441-197901000-00002 1:STN:280:DyaE1M7kt1Gjsg%3D%3D
4. HL Janssen M van Zonneveld H Senturk, et al. 2005 Pegylated interferon alpha-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 9454 123 129 15639293 10.1016/S0140-6736(05)17701-0 1:CAS:528:DC%2BD2MXhvF2gsQ%3D%3D
5. TT Chang CL Lai S KewYoon, et al. 2010 Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2 422 430 20049753 10.1002/hep.23327 1:CAS:528: DC%2BC3cXisVGgurs%3D
6. EJ Heathcote P Marcellin M Buti, et al. 2011 Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 1 132 143 20955704 10.1053/j.gastro.2010.10.011 1:CAS:528:DC%2BC3cXhsFyltLvF
7. MF Yuen DK Wong E Sablon, et al. 2004 HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects Hepatology 39 6 1694 1701 15185311 10.1002/hep.20240
8. MA Loriot P Marcellin F Walker, et al. 1997 Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg J Hepatol 27 2 251 258 9288597 10.1016/S0168-8278(97)80168-7 1:CAS:528:DyaK2sXlvFars7k%3D
9. MF Yuen DK Wong J Fung, et al. 2008 HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma Gastroenterology 135 4 1192 1199 18722377 10.1053/j.gastro.2008.07.008 1:CAS:528:DC%2BD1cXht12lurrP
10. J Simonetti L Bulkow BJ McMahon, et al. 2010 Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus Hepatology 51 5 1531 1537 20087968 10.1002/hep.23464
11. H Kim EJ Oh MS Kang, et al. 2007 Comparison of the Abbott Architect i2000 assay, the Roche Modular Analytics E170 assay, and an immunoradiometric assay for serum hepatitis B virus markers Ann Clin Lab Sci 37 3 256 259 17709690
12. A Mühlbacher B Weber P Bürgisser, et al. 2008 Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants Med Microbiol Immunol 197 1 55 64 17899185 10.1007/s00430-007-0059-9
13. N Matsubara O Kusano Y Sugamata, et al. 2009 A novel hepatitis B virus surface antigen immunoassay as sensitive as hepatitis B virus nucleic acid testing in detecting early infection Transfusion 49 3 585 595 19192255 10.1111/j.1537-2995.2008.02026.x
14. B Weber 2005 Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact J Clin Virol 32 2 102 112 15653412 10.1016/j.jcv.2004.10.008 1:CAS:528:DC%2BD2MXkvFChuw%3D%3D
15. T Kimura A Rokuhara Y Sakamoto, et al. 2002 Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load J Clin Microbiol 40 2 439 445 11825954 10.1128/JCM.40.2.439-445.2002 1:CAS:528:DC%2BD38XhvFGktbk%3D
16. DK Wong Y Tanaka CL Lai, et al. 2007 Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection J Clin Microbiol 45 12 3942 3947 17942661 10.1128/JCM.00366-07 1:CAS:528: DC%2BD1cXntlWnug%3D%3D
17. A Rokuhara E Tanaka A Matsumoto, et al. 2003 Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment J Viral Hepatitis 10 4 324 330 10.1046/j.1365-2893.2003.00437.x 1:STN:280:DC%2BD3s3ps1yhsQ%3D%3D
18. N Shinkai Y Tanaka K Matsuura, et al. 2010 Evaluation and application of a newly developed highly sensitive HBsAg chemiluminescent enzyme immunoassay for chronic hepatitis B patients Rinsho Byori 58 11 1078 1084 21229705
19. Shinkai N, Tanaka Y, Matsuura K, et al. Evaluation and application of a novel high-sensitive chemiluminescent enzyme immunoassay for chronic hepatitis B patients with HBsAg seroconversion. Hepatology 2010;52(4):458A (abstract)
20. CM Chu YF Liaw 2007 HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up Hepatology 45 5 1187 1192 17465003 10.1002/hep.21612
21. C Brechot V Thiers D Kremsdorf, et al. 2001 Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 34 1 194 203 11431751 10.1053/jhep.2001.25172 1:STN:280:DC%2BD3MznsVKnuw%3D%3D
22. MF Yuen CK Lee DK Wong, et al. 2010 Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population Gut 59 10 1389 1393 20675695 10.1136/gut.2010.209148
23. Seo DH, Whang DH, Song EY, et al. Prevalence of antibodies to hepatitis B core antigen and occult hepatitis B virus infections in Korean blood donors. Transfusion 2011;51(8):1840-1846
24. J Hou Z Wang J Cheng, et al. 2001 Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers Hepatology 34 5 1027 1034 11679975 10.1053/jhep.2001.28708 1:CAS:528:DC%2BD3MXotlyqsbY%3D
25. J Verheyen M Neumann-Fraune T Berg, et al. 2011 Mutations in the HBs-antigen influence the results of HBsAg quantification assays J Hepatol 54 Suppl S158 10.1016/S0168-8278(11)60396-6
26. RJ Gilbert L Beales D Blond, et al. 2005 Hepatitis B small surface antigen particles are octahedral Proc Natl Acad Sci USA 102 41 14783 14788 16203986 10.1073/pnas.0505062102 1:CAS:528:DC%2BD2MXhtFKjsbzO
27. J Fung CL Lai MF Yuen 2010 Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B Expert Rev Anti Infect Ther 8 6 717 726 20521898 10.1586/eri.10.45 1:CAS:528:DC%2BC3cXmvFaqtbo%3D
28. P Vanlandschoot G Leroux-Roels 2003 Viral apoptotic mimicry: an immune evasion strategy developed by the hepatitis B virus? Trends Immunol 24 3 144 147 12615210 10.1016/S1471-4906(03)00026-7 1:CAS:528:DC%2BD3sXhs1WgtLw%3D
29. HP Dienes WH Gerlich M Worsdorfer, et al. 1990 Hepatic expression patterns of the large and middle hepatitis B virus surface proteins in viremic and nonviremic chronic hepatitis B Gastroenterology 98 4 1017 1023 2179028 10.1016/0016-5085(90)90028-Y 1:STN:280:DyaK3c7osV2ktQ%3D%3D
30. B Werle-Lapostolle S Bowden S Locarnini, et al. 2004 Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology 126 7 1750 1758 15188170 10.1053/j.gastro.2004.03.018 1:CAS:528:DC%2BD2cXlsFaqs78%3D
31. T Volz M Lutgehetmann P Wachtler, et al. 2007 Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients Gastroenterology 133 3 843 852 17854594 10.1053/j.gastro.2007.06.057 1:CAS:528:DC%2BD2sXhtFarsrfP
32. AJ Thompson T Nguyen D Iser, et al. 2010 Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers Hepatology 51 6 1933 1944 20512987 10.1002/hep.23571 1:CAS:528:DC%2BC3cXnslyqsLc%3D
33. CA Bill J Summers 2004 Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration Proc Natl Acad Sci USA 101 30 11135 11140 15258290 10.1073/pnas.0403925101 1:CAS:528:DC%2BD2cXmsVCmtb0%3D
34. Fung J, Lai CL, Young J, et al. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol 2011;10:1766-1773
35. W Yeo PJ Johnson 2006 Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy Hepatology 43 2 209 220 16440366 10.1002/hep.21051 1:CAS:528:DC%2BD28XhvVSgu7o%3D
36. R Moucari M Martinot-Peignoux V Mackiewicz, et al. 2009 Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a Antivir Ther 14 8 1183 1188 20032548 10.3851/IMP1458 1:CAS:528:DC%2BC3cXitVyqu70%3D